Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Did a workplace sugar-sweetened beverage sales ban reduce anxiety-related sugar-sweetened beverage consumption during the COVID-19 pandemic?

Public health nutrition·2024
Same author

Comparison of the efficacy of dispensing granules with traditional decoction: a systematic review and meta-analysis.

Annals of translational medicine·2018
Same author

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis.

Journal of digestive diseases·2018
Same author

Acupuncture for constipation in patients with stroke: protocol of a systematic review and meta-analysis.

BMJ open·2018
Same author

Toward universal influenza virus vaccines: from natural infection to vaccination strategy.

Current opinion in immunology·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Armen Moughamian1, Shawn Kile2, Jane Kim1

  • 1Ray Dolby Brain Health Center, Sutter Health, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Lecanemab, un nuevo tratamiento para el Alzheimer, mostró tasas más bajas de anomalías de imagen relacionadas con amiloide (ARIA) en un entorno comunitario en comparación con los ensayos clínicos. Esto sugiere que lecanemab se puede administrar de forma segura fuera de los centros especializados.

Palabras clave:
LecanemabEnfermedad de AlzheimerAnomalías de imagen relacionadas con amiloideEnsayo clínicoAtención médica comunitaria

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurología
  • Farmacología
  • Medicina Clínica

Sus antecedentes:

  • Lecanemab es la primera terapia modificadora de la enfermedad aprobada por la FDA para la enfermedad de Alzheimer.
  • Las anomalías de imagen relacionadas con amiloide (ARIA) son un efecto secundario importante asociado con el tratamiento con lecanemab.
  • Existe incertidumbre sobre la frecuencia y gravedad de las ARIA en la práctica clínica del mundo real.

Objetivo del estudio:

  • Resumir la experiencia con el tratamiento con lecanemab en un sistema de atención médica basado en la comunidad.
  • Evaluar la seguridad y tolerabilidad de lecanemab en una cohorte de pacientes del mundo real.
  • Comparar las tasas de ARIA en un entorno comunitario con los hallazgos del ensayo CLARITY-AD de fase 3.

Principales métodos:

  • Se recopilaron datos de pacientes que recibieron lecanemab entre julio de 2023 y junio de 2024.
  • La elegibilidad se determinó según la etiqueta de la FDA y las Recomendaciones de Uso Apropiado.
  • Se centró en pacientes con al menos 6 meses de tratamiento con lecanemab para capturar el período de mayor riesgo de ARIA.

Principales resultados:

  • 210 pacientes tratados (edad media 75 años, 52 % mujeres); 70 % con deterioro cognitivo leve, 30 % con demencia leve.
  • 36 % experimentó reacciones a la infusión (en su mayoría leves); 14 % interrumpió lecanemab.
  • 15,7 % experimentó ARIA (13,8 % ARIA-H, 7,6 % ARIA-E); 8 casos de ARIA radiográfica grave; 3 casos de ARIA sintomática.

Conclusiones:

  • Lecanemab se puede administrar de forma segura en un gran sistema de atención médica basado en la comunidad.
  • Se observaron tasas más altas de reacciones a la infusión pero tasas más bajas de ARIA en comparación con el ensayo CLARITY-AD.
  • Las tasas más bajas de ARIA en portadores no de ApoE4 y heterocigotos sugieren una administración segura en entornos comunitarios.